Investigating the trends of incidence rates of breast cancer in Southern Iran: a population based survey.
Age group
Breast cancer
Incidence trend
Morphology
Topography
Journal
BMC women's health
ISSN: 1472-6874
Titre abrégé: BMC Womens Health
Pays: England
ID NLM: 101088690
Informations de publication
Date de publication:
10 11 2023
10 11 2023
Historique:
received:
01
10
2022
accepted:
01
11
2023
medline:
13
11
2023
pubmed:
11
11
2023
entrez:
10
11
2023
Statut:
epublish
Résumé
The overall incidence of breast cancer is different all over the world and even within a nation. The present study aims to investigate the stratum-specific incidence trends of breast cancer in southern Iran. In this retrospective cohort study, the data of Fars Population-Based Cancer Registry was used during 2001-2018. New cancer cases with ICD-O-3 codes C50.0 to C50.9 were categorized based on age group, morphology, and topography. Age-specific incidence rates of breast cancer were calculated during 2001-2018. Annual overall and truncated age-standardized incidence rates and their 95% Confidence Intervals (CIs) were also calculated. Afterward, the Annual Percentage Changes (APCs) of the age-specific and age-standardized incidence rates of breast cancer during 2001-2018 were calculated using Joinpoint regression software. An increasing trend was observed in the incidence of breast cancer among women during 2001-2018 (APC of age-standardized incidence rates: 9.5 (95% CI: 7.5, 11.5)).However, the trend was increasing less during the recent years. The APC of age-standardized rates decreased from 15.03 (95% CI: 10.4, 19.8) in 2007 to 6.15(95% CI: 4.0, 8.4) in 2018. The most common morphology of breast cancer was invasive ductal carcinoma (77.3% in females and 75.1% in males) and its trend was similar to the general trend of different types of breast cancer. The most common site of breast cancer was the upper outer quadrant. Most breast cancer cases were female and males accounted for 2.45% of the cases. Among females, 40-55 was the most prevalent age group. The incidence of breast cancer among women living in southern Iran showed an increasing trend from 2001 to 2018. However, the rate of increase exhibited a milder slope during the more recent years. Based on the higher prevalence of breast cancer in the 40-55 age group observed in the present study, it offers valuable insight into the potential reduction of the breast cancer screening age from 50 to 40 years for healthy Iranian women. However, before implementing such a policy change, it is crucial to conduct additional studies that specifically examine the cost-effectiveness, as well as the potential benefits and risks associated with this alteration.
Sections du résumé
BACKGROUND
The overall incidence of breast cancer is different all over the world and even within a nation. The present study aims to investigate the stratum-specific incidence trends of breast cancer in southern Iran.
METHODS
In this retrospective cohort study, the data of Fars Population-Based Cancer Registry was used during 2001-2018. New cancer cases with ICD-O-3 codes C50.0 to C50.9 were categorized based on age group, morphology, and topography. Age-specific incidence rates of breast cancer were calculated during 2001-2018. Annual overall and truncated age-standardized incidence rates and their 95% Confidence Intervals (CIs) were also calculated. Afterward, the Annual Percentage Changes (APCs) of the age-specific and age-standardized incidence rates of breast cancer during 2001-2018 were calculated using Joinpoint regression software.
RESULTS
An increasing trend was observed in the incidence of breast cancer among women during 2001-2018 (APC of age-standardized incidence rates: 9.5 (95% CI: 7.5, 11.5)).However, the trend was increasing less during the recent years. The APC of age-standardized rates decreased from 15.03 (95% CI: 10.4, 19.8) in 2007 to 6.15(95% CI: 4.0, 8.4) in 2018. The most common morphology of breast cancer was invasive ductal carcinoma (77.3% in females and 75.1% in males) and its trend was similar to the general trend of different types of breast cancer. The most common site of breast cancer was the upper outer quadrant. Most breast cancer cases were female and males accounted for 2.45% of the cases. Among females, 40-55 was the most prevalent age group.
CONCLUSION
The incidence of breast cancer among women living in southern Iran showed an increasing trend from 2001 to 2018. However, the rate of increase exhibited a milder slope during the more recent years. Based on the higher prevalence of breast cancer in the 40-55 age group observed in the present study, it offers valuable insight into the potential reduction of the breast cancer screening age from 50 to 40 years for healthy Iranian women. However, before implementing such a policy change, it is crucial to conduct additional studies that specifically examine the cost-effectiveness, as well as the potential benefits and risks associated with this alteration.
Identifiants
pubmed: 37950182
doi: 10.1186/s12905-023-02757-7
pii: 10.1186/s12905-023-02757-7
pmc: PMC10638837
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
589Informations de copyright
© 2023. The Author(s).
Références
Clin Med Insights Pathol. 2015 Dec 21;8:23-31
pubmed: 26740749
Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2496-502
pubmed: 20802021
EClinicalMedicine. 2021 Jul 07;38:100985
pubmed: 34278281
Breast. 2005 Apr;14(2):151-2
pubmed: 15767185
J Mammary Gland Biol Neoplasia. 2019 Dec;24(4):333-342
pubmed: 31807966
Int J Cancer. 2003 Sep 20;106(5):771-83
pubmed: 12866039
Surg Clin North Am. 2013 Apr;93(2):363-92
pubmed: 23464691
Asian Pac J Cancer Prev. ;18(5):1411-1416
pubmed: 28612595
Afr Health Sci. 2021 Mar;21(1):47-53
pubmed: 34394280
Cancer Clin Oncol. 2015;4(2):24-31
pubmed: 26251693
Cancer Epidemiol Biomarkers Prev. 2018 Oct;27(10):1214-1222
pubmed: 30068516
Asian Pac J Cancer Prev. 2021 Dec 01;22(12):3889-3896
pubmed: 34967568
Ecancermedicalscience. 2015 Jul 13;9:552
pubmed: 26284116
Annu Rev Public Health. 1996;17:47-67
pubmed: 8724215
Am J Epidemiol. 2017 Dec 15;186(12):1329-1340
pubmed: 28637226
BMC Cancer. 2015 Mar 18;15:138
pubmed: 25880075
Eur J Cancer. 2014 Jul;50(10):1808-1818
pubmed: 24767469
BMC Health Serv Res. 2013 May 06;13:169
pubmed: 23647828
Lancet. 2008 Feb 16;371(9612):569-78
pubmed: 18280327
Horm Mol Biol Clin Investig. 2020 Oct 21;41(4):
pubmed: 33079703
Gland Surg. 2014 Nov;3(4):237-42
pubmed: 25493255
J Gastrointest Cancer. 2022 Dec;53(4):841-847
pubmed: 34792757
Adv Exp Med Biol. 2019;1152:1-7
pubmed: 31456176
Medicina (Kaunas). 2021 Jan 12;57(1):
pubmed: 33445543
PLoS One. 2021 Feb 10;16(2):e0246800
pubmed: 33566857
Cancer Commun (Lond). 2021 Nov;41(11):1183-1194
pubmed: 34399040
JAMA. 2012 Apr 4;307(13):1394-404
pubmed: 22474203
BMC Womens Health. 2020 Mar 17;20(1):53
pubmed: 32183824
Cell Metab. 2014 Mar 4;19(3):407-17
pubmed: 24606898
Br J Cancer. 2002 Nov 18;87(11):1234-45
pubmed: 12439712
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1507-14
pubmed: 19423528
J Med Life. 2019 Apr-Jun;12(2):140-149
pubmed: 31406515
Anticancer Res. 2005 May-Jun;25(3c):2543-50
pubmed: 16080490
Indian J Radiol Imaging. 2009 Jul-Sep;19(3):242-7
pubmed: 19881096
Int J Surg. 2014;12(5):394-8
pubmed: 24657350
Am J Surg. 2008 May;195(5):641-4
pubmed: 18424280
Radiology. 2021 Apr;299(1):143-149
pubmed: 33560186
Cancer. 2000 May 15;88(10):2398-424
pubmed: 10820364
J Gastrointest Cancer. 2022 Mar;53(1):230-234
pubmed: 34855123